WO2017133337A1 - 一种取代的苯并咪唑酮化合物及包含该化合物的组合物 - Google Patents
一种取代的苯并咪唑酮化合物及包含该化合物的组合物 Download PDFInfo
- Publication number
- WO2017133337A1 WO2017133337A1 PCT/CN2016/111193 CN2016111193W WO2017133337A1 WO 2017133337 A1 WO2017133337 A1 WO 2017133337A1 CN 2016111193 W CN2016111193 W CN 2016111193W WO 2017133337 A1 WO2017133337 A1 WO 2017133337A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- receptor
- pharmaceutically acceptable
- disorder
- substituted benzimidazolone
- Prior art date
Links
- -1 benzimidazolone compound Chemical class 0.000 title claims abstract description 25
- 239000000203 mixture Chemical class 0.000 title abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 94
- 239000003814 drug Substances 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 239000012453 solvate Substances 0.000 claims abstract description 7
- 230000000155 isotopic effect Effects 0.000 claims abstract description 6
- 229940002612 prodrug Drugs 0.000 claims abstract 4
- 239000000651 prodrug Substances 0.000 claims abstract 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 206010057671 Female sexual dysfunction Diseases 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 8
- 206010057672 Male sexual dysfunction Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 201000007930 alcohol dependence Diseases 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 229910052805 deuterium Inorganic materials 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 206010000117 Abnormal behaviour Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000032841 Bulimia Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 206010028403 Mutism Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 206010043903 Tobacco abuse Diseases 0.000 claims description 2
- 208000025748 atypical depressive disease Diseases 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000001066 destructive effect Effects 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000006984 memory degeneration Effects 0.000 claims description 2
- 208000023060 memory loss Diseases 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 22
- 241001465754 Metazoa Species 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 34
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 201000001880 Sexual dysfunction Diseases 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 231100000872 sexual dysfunction Toxicity 0.000 description 8
- 239000012265 solid product Substances 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 239000000883 anti-obesity agent Substances 0.000 description 7
- 229940125710 antiobesity agent Drugs 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 5
- 108091005479 5-HT2 receptors Proteins 0.000 description 5
- 102000008873 Angiotensin II receptor Human genes 0.000 description 5
- 108050000824 Angiotensin II receptor Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 229910052712 strontium Inorganic materials 0.000 description 5
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 5
- 0 CC(C)C(C)(C)[S+]CCOCN(c(cccc1)c1N1CCN(C2(*)C3(*)*2)C(*)(*)C(*)(*)N3c2cc(C(F)(F)F)ccc2)C1=O Chemical compound CC(C)C(C)(C)[S+]CCOCN(c(cccc1)c1N1CCN(C2(*)C3(*)*2)C(*)(*)C(*)(*)N3c2cc(C(F)(F)F)ccc2)C1=O 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 4
- 208000021663 Female sexual arousal disease Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 4
- 229960001243 orlistat Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 101710151321 Melanostatin Proteins 0.000 description 3
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 3
- 102400000064 Neuropeptide Y Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940127204 compound 29 Drugs 0.000 description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 3
- 229960004425 sibutramine Drugs 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 102000054930 Agouti-Related Human genes 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 101710095342 Apolipoprotein B Proteins 0.000 description 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000013585 Bombesin Human genes 0.000 description 2
- 108010051479 Bombesin Proteins 0.000 description 2
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010016122 Ghrelin Receptors Proteins 0.000 description 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 2
- 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 229940122942 Leptin receptor agonist Drugs 0.000 description 2
- 101000680845 Luffa aegyptiaca Ribosome-inactivating protein luffin P1 Proteins 0.000 description 2
- 108010000410 MSH receptor Proteins 0.000 description 2
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 102100023206 Neuromodulin Human genes 0.000 description 2
- 101710144282 Neuromodulin Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000005630 Urocortins Human genes 0.000 description 2
- 108010059705 Urocortins Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- 229960002802 bromocriptine Drugs 0.000 description 2
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 2
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 2
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003667 hormone antagonist Substances 0.000 description 2
- 229940125425 inverse agonist Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 2
- DYGBNAYFDZEYBA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-n-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(CC(=O)N(CC2CC2)CC=2NC(=O)C=3COCCC=3N=2)CC1 DYGBNAYFDZEYBA-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 229940076372 protein antagonist Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002469 receptor inverse agonist Substances 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940127230 sympathomimetic drug Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000000777 urocortin Substances 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- HKLYDUXIXBVZOQ-UHFFFAOYSA-N 2-aminoethane-1,1,1-triol Chemical class NCC(O)(O)O HKLYDUXIXBVZOQ-UHFFFAOYSA-N 0.000 description 1
- MLFIYYDKLNZLAO-UHFFFAOYSA-N 2-aminoethane-1,1-diol Chemical class NCC(O)O MLFIYYDKLNZLAO-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- CCIZQGRSEAHATK-UHFFFAOYSA-N 3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1h-benzimidazol-2-one Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCN(CCN2C(NC3=CC=CC=C32)=O)CC1 CCIZQGRSEAHATK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XYVMOLOUBJBNBF-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical compound OC1=NC=CO1 XYVMOLOUBJBNBF-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940122203 Bombesin receptor antagonist Drugs 0.000 description 1
- NCDZRUQAKVGQFI-UHFFFAOYSA-N C[Si](C)(C)CCOCN(c(cccc1)c1N1CCBr)C1=O Chemical compound C[Si](C)(C)CCOCN(c(cccc1)c1N1CCBr)C1=O NCDZRUQAKVGQFI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- LIGBGEJPUQBLTG-UHFFFAOYSA-N FC(c1cc(F)cc(Br)c1)(F)F Chemical compound FC(c1cc(F)cc(Br)c1)(F)F LIGBGEJPUQBLTG-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000019432 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229940123730 Orexin receptor antagonist Drugs 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012512 bulk drug substance Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 description 1
- 229960002053 flibanserin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical group [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000005445 isotope effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 239000000336 melanocortin receptor agonist Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 230000000407 monoamine reuptake Effects 0.000 description 1
- 229940126403 monoamine reuptake inhibitor Drugs 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 208000024309 orgasm disease Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940076155 protein modulator Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000035936 sexual power Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
Definitions
- the invention belongs to the technical field of medicine, and in particular to a substituted benzimidazolone compound and a composition comprising the same.
- the serum angiotensin (5-hydroxytryptamine, 5-HT) receptor is an important G protein-coupled receptor. Serum tension is thought to play a role in processes related to learning and memory, sleep, temperature regulation, mood, spontaneous activity, pain, sexual and aggressive behavior, appetite, neurodegeneration, and biological rhythms. As expected, serum angiotensin is associated with disease physiology such as anxiety, depression, obsessive-compulsive disorder, schizophrenia, suicide, autism, migraine, vomiting, alcoholism, and neurodegenerative disorders.
- 5-HT2 receptor is currently divided into three subtypes: 5-HT2a, 5-HT2b, and 5-HT2c.
- the three subtypes of the 5-HT2 receptor are associated with the production of two second messengers: diacylglycerol (which activates protein kinase C) and inositol triphosphate (which releases intracellularly stored Ca2+) phospholipase C. Connected.
- the present invention discloses a substituted benzimidazolone compound and a composition comprising the same, which has better serum angiotensin receptor inhibitory activity and/or has better pharmacodynamics/pharmacokinetics Kinetic performance.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 are each independently hydrogen, deuterium, halogen or trifluoromethyl;
- X is C, N;
- At least one of R 17 , R 18 , R 19 , R 20 and R 21 is ⁇ .
- the shape and volume of hydrazine in the drug molecule are substantially the same as hydrogen. If the hydrogen in the drug molecule is selectively replaced with hydrazine, the deuterated drug generally retains its original biological activity and selectivity. At the same time, the inventors have confirmed through experiments that the binding of carbon-germanium bonds is more stable than the combination of carbon-hydrogen bonds, which can directly affect the absorption, distribution, metabolism and excretion of some drugs, thereby improving the efficacy, safety and tolerability of the drugs.
- the strontium isotope content of strontium at each metamorphic position is at least greater than the natural strontium isotope content (0.015%), preferably greater than 30%, more preferably greater than 50%, and even more preferably greater than 75%. More preferably greater than 95%, more preferably greater than 99%.
- the strontium isotope content of each of R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 in the deuterated position is at least 5%, preferably more than 10%, more preferably more than 15%, more preferably More than 20%, more preferably more than 25%, more preferably more than 30%, more preferably more than 35%, more preferably more than 40%, more preferably more than 45%, more preferably more than 50%, more preferably more than 55%, more preferably more than 60%, more preferably more than 65%, more preferably more than 70%, more preferably more than 75%, more preferably more than 80%, more preferably more than 85%, more preferably more than 90 %, more preferably greater than 95%, and even more preferably greater than
- R 18 is a trifluoromethyl group.
- R 1 , R 2 , R 3 and R 4 are each independently hydrazine or hydrogen.
- R 5 , R 6 , R 7 and R 8 are each independently hydrazine or hydrogen.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently hydrazine or hydrogen.
- R 17 , R 19 , R 20 and R 21 are each independently hydrazine or hydrogen.
- R 1 , R 2 , R 3 and R 4 are ⁇ .
- R 5 , R 6 , R 7 and R 8 are ⁇ .
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are ⁇ .
- R 17 , R 19 , R 20 , and R 21 are ⁇ .
- the compound is selected from the group consisting of the compounds or pharmaceutically acceptable salts thereof:
- the compound does not include a non-deuterated compound.
- the non-deuterated compound is 3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzo Imidazol-2-one.
- a method of preparing a pharmaceutical composition comprising the steps of: pharmaceutically acceptable carrier and a compound of the first aspect of the invention, or a crystalline form thereof, pharmaceutically acceptable
- the accepted salt, hydrate or solvate is mixed to form a pharmaceutical composition.
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the first aspect of the invention, or a crystalline form thereof, a pharmaceutically acceptable salt, hydrated Or a solvate.
- the pharmaceutical composition is an injection, a sachet, a tablet, a pill, a powder or a granule.
- the compounds of the present invention can be administered in combination with other drugs, such as apolipoprotein-B/MTP inhibitors, MCR-4 agonists, CCK-A agonists, monoamine reuptake inhibitors, sympathomimetic drugs, ⁇ 3 adrenaline.
- drugs such as apolipoprotein-B/MTP inhibitors, MCR-4 agonists, CCK-A agonists, monoamine reuptake inhibitors, sympathomimetic drugs, ⁇ 3 adrenaline.
- Receptor agonist dopamine agonist, melanocyte stimulating hormone receptor analogue, cannabinoid 1 receptor antagonist, melanin concentration hormone antagonist, leptin, leptin analogue, leptin receptor agonist, gan a propanoid antagonist, a lipase inhibitor, a bombesin agonist, a neuropeptide-Y antagonist, a thyroxine drug, dehydroepiandrosterone or an analogue thereof, a glucocorticoid receptor agonist or antagonist, Orexin receptor antagonist, urocortin-binding protein antagonist, glucagon-like peptide-1 receptor agonist, ciliary neurotrophic factor, AGRPs (human wild ash related protein), ghrelin Receptor antagonist, histamine 3 receptor antagonist or inverse agonist, neuromodulin U receptor Agonists and the like.
- AGRPs human wild ash related protein
- ghrelin Receptor antagonist histamine 3 receptor antagonist or inverse agonist
- Combination therapies can be administered in the following manner: (1) a single pharmaceutical composition comprising a compound of the invention, at least one other agent as described above, and a pharmaceutically acceptable excipient, diluent or carrier; or (2) Two separate pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable excipient, diluent or carrier.
- the pharmaceutical compositions can be administered simultaneously or sequentially and in any order.
- kits for use in a consumer for the treatment of a 5-HT2 receptor-mediated disease, condition or disorder in an animal comprises a) a suitable dosage form comprising a compound of the invention; and b) instructions for describing a method of treating or preventing a 5-HT2 receptor-mediated disease, condition or disorder using the dosage form.
- Another embodiment of the invention is a pharmaceutical kit comprising: a) a first dosage form comprising (i) a compound of the invention and (ii) a pharmaceutically acceptable carrier, excipient or diluent; b) A second dosage form comprising (i) one of the other agents as described above, and (ii) a pharmaceutically acceptable carrier, excipient or diluent; and c) a container.
- Another aspect of the invention is a method of treating female sexual dysfunction (FSD) comprising the step of administering to a female in need of such treatment a therapeutically effective amount of a compound of the invention.
- the method can further comprise administering one or more additional active agents for treating FSD.
- the additional active agent may be selected from the group consisting of: (1) an estrogen receptor protein modulator, an estrogen agonist, an estrogen antagonist, or a combination thereof; (2) a testosterone replacement agent, testosterone, dihydrotestosterone, dehydroepiandroindole Ketone, testosterone implant or combination thereof; (3) a combination of estrogen, estrogen and medroxyprogesterone or medroxyprogesterone acetate, or estrogen and methyltestosterone hormone instead of a therapeutic agent; (4) one or more a dopaminergic agent; (5) one or more NPY (neuropeptide Y) inhibitors; (6) one or more melanocortin receptor agonists or modulators or melanocortin enhancers; (7) one or a plurality of neutral endopeptidase (NEP) inhibitors; (8) one or more phosphodiesterase (PDE) inhibitors; and (9) one or more bombesin receptor antagonists or modulators.
- FSD treatment includes female sexual arousal disorder
- the invention also includes isotopically labeled compounds, equivalent to the original compounds disclosed herein.
- isotopes which may be listed as compounds of the present invention include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine isotopes such as 2 H, 3 H, 13 C, 14 C, 15 N, 17 O, 18 O, respectively. , 31 P, 32 P, 35 S, 18 F and 36 Cl. a compound, or an enantiomer, a diastereomer, an isomer, or a pharmaceutically acceptable salt or solvate of the present invention, wherein an isotope or other isotopic atom containing the above compound is within the scope of the present invention .
- isotopically-labeled compounds of the present invention such as the radioisotopes of 3 H and 14 C, are also among them, useful in tissue distribution experiments of drugs and substrates. ⁇ , ie 3 H and carbon-14, ie 14 C, are easier to prepare and detect and are preferred in isotopes.
- heavier isotopic substitutions such as guanidine, or 2 H, are advantageous in certain therapies due to their good metabolic stability, such as increased half-life or reduced dosage in vivo, and therefore may be preferred in some cases.
- Isotopically labeled compounds can be prepared in a conventional manner by substituting a readily available isotopically labeled reagent with a non-isotopic reagent using the protocol of the examples.
- the compounds of the invention are useful as a 5HT 2 partial agonist or antagonist; therefore, another embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable excipient, diluted Agent or carrier.
- a typical preparation is prepared by mixing a compound of the invention with a carrier, diluent or excipient.
- Suitable carriers, diluents and excipients are well known to those skilled in the art and include materials such as carbohydrates, paraffin, water soluble and/or swellable polymers, hydrophilic or hydrophobic materials, gelatin, Oil, solvent, water, etc.
- the particular carrier, diluent or excipient used will depend on the mode and purpose of the application of the compound of the invention.
- the solvent is typically selected from solvents which are considered safe to the mammal to be administered by those skilled in the art. Generally, safe solvents are non-toxic aqueous solvents such as water and other non-toxic solvents that are soluble or miscible in water.
- Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycol (e.g., PEG400, PEG300), and the like, and mixtures thereof.
- the formulation may also include one or more buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, light protectants, glidants, process auxiliaries, Colorants, sweeteners, flavors, flavorings, and other known additives to provide a delicate appearance of the drug (ie, a compound of the invention or a pharmaceutical composition thereof), or to aid in the manufacture of a medicament (ie, a drug) .
- the pharmaceutical composition (or formulation) for administration can be packaged in various ways, depending on the method of administration used.
- the dispensed article includes a container in which the pharmaceutical formulation can be placed in a suitable form.
- suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), pouches, ampoules, plastic bags, metal cylinders and the like.
- the container may also include an interference-proof fitting to prevent indiscreet use of the contents of the package.
- a label is placed on the container to record the contents of the container. Tags can also include appropriate warnings.
- the present invention still further provides a method of treating 5HT 2 receptors in need of such treatment an animal - a disease mediated condition or disorder comprising administering to the animal a therapeutically effective amount of a compound of the invention or comprising an effective amount of a compound of the invention and A pharmaceutical composition of a pharmaceutically acceptable excipient, diluent or carrier.
- the method may be particularly useful for the treatment of 5HT 2 receptors - a disease, condition or disorder mediated.
- the compounds of the present invention as the 5HT 2 receptor partial agonist. More preferably, the compounds of this invention as agonists of 5HT 2 receptors and act partially to the 5HT 2 receptor antagonist.
- the 5HT 2 receptor-mediated disease, condition or disorder is selected from the group consisting of: weight loss (eg, decreased caloric intake), obesity, bulimia, premenstrual syndrome or delayed luteal phase syndrome, depression , atypical depression, manic depressive psychosis, psychosis, schizophrenia, migraine, alcoholism, tobacco abuse, panic disorder, anxiety, post-traumatic syndrome, memory loss, senile dementia, social phobia, attention deficit Obstacle with ADHD, destructive behavior disorder, impulsive control disorder, critical personality disorder, obsessive compulsive disorder, chronic fatigue syndrome, male sexual dysfunction (eg, premature ejaculation and erectile dysfunction), female sexual dysfunction, anorexia nervosa, Sleep disorders (eg, sleep apnea), autism, seizures, epilepsy, mutism, spinal cord injury, central nervous system damage (eg, trauma, stroke, neurodegenerative disease, or toxic or infectious CNS disease (eg, brain) Inflammation or meningitis)), cardiovascular disease
- the compounds of the invention described herein are useful for the treatment or prevention of 5-HT2 receptor-mediated diseases, conditions or disorders.
- the compounds of the invention including compositions and methods used therein, can be used in the manufacture of a medicament for use in the therapeutic applications described herein.
- the compounds of the invention may be administered to a patient at a dosage level of from about 0.7 mg to about 7,000 mg per day. For adults with a normal body weight of about 70 kilograms, a dose of from about 0.01 milligrams to about 100 milligrams per kilogram of body weight is typically sufficient.
- typical dosage ranges may vary depending on the age and weight of the patient to be treated, the route of administration, the particular compound being administered, and the like. Determination of the dosage range and optimal dosage for a particular patient is within the capabilities of one of ordinary skill in the art having the benefit of this disclosure. It should also be noted that the compounds of the present invention can be used in the form of sustained release, controlled release and delayed release formulations, which are well known to those of ordinary skill in the art.
- Suitable drugs that can be used in combination with the compounds of the invention include anti-obesity agents such as apolipoprotein-B secretion/microsomal triglyceride transfer protein (apo-B/MTP) inhibitors, MCR-4 agonists, cholecystectomy a peptide-A (CKK-A) agonist, a monoamine reuptake inhibitor (such as sibutramine), a sympathomimetic agent, a beta 3 adrenergic receptor agonist, a dopamine agonist (such as bromocriptine), Melanocyte stimulating hormone receptor analogue, cannabinoid 1 receptor antagonist, melanin concentration hormone antagonist, lean hormone (OB protein), leptin analog, leptin receptor agonist, galanin antagonist, fat Enzyme
- anti-obesity agents such as apolipoprotein-B secretion/microsomal triglyceride transfer protein (apo-B/MTP) inhibitors, MCR-4 agonists,
- anti-obesity agents are selected from the group consisting of: orlistat, sibutramine, bromocriptine, ephedrine, leptin and pseudoephedrine.
- the compounds of the invention, as well as combination therapies, should be combined with exercise and a reasonable diet.
- anti-obesity agents for use in combination, pharmaceutical compositions, and methods of the invention can be prepared using methods well known to those of ordinary skill in the art, for example, sibutramine can be prepared as described in U.S. Patent 4,929,629; The bromo ergocycline can be prepared as described in U.S. Patent Nos. 3,752,814 and 3,752,888; and orlistat can be prepared as described in U.S. Patent Nos. 5,274,143; 5,420,305; 5,540,917; and 5,643,874. All of the above-referenced U.S. patents are incorporated herein by reference.
- the dosage of other drugs will also generally depend on a number of factors, including the health of the patient to be treated, the degree of treatment required, the nature and type of treatment (if any), and The number of treatments and the nature of the target effect.
- the anti-obesity agent will be administered in a dosage range of from about 0.001 mg to about 100 mg per kilogram of body weight per day, preferably from about 0.1 mg to about 10 mg per kilogram of body weight per person per day.
- the usual dosage range may also vary depending on the age and weight of the patient to be treated, the route of administration, the particular anti-obesity agent administered, and the like. Determination of the dosage range and optimal dosage for a particular patient is also within the capabilities of one of ordinary skill in the art having the benefit of this disclosure.
- the compounds of the invention are found to be useful in the treatment of sexual dysfunction.
- Sexual dysfunction is a notable clinical problem that can be affected by both male and female animals.
- the cause of SD can be either organic or psychological.
- the SD in terms of organics is typically caused by underlying vascular diseases such as vascular diseases associated with hypertension or diabetes, by prescription drugs and/or by psychotic diseases such as depression.
- Physiological factors include fear, behavioral anxiety, and interpersonal conflict. SD jeopardizes sexual behavior, weakens self-esteem, and undermines interpersonal relationships, thereby causing personal suffering.
- SD disorders are divided into female sexual function (FSD) disorders and male sexual dysfunction (MSD).
- FSD can be clearly defined as the difficulty or incompetence of women's satisfaction with sexual performance.
- MSD is commonly associated with erectile dysfunction, also known as male erectile dysfunction (MED) (Benet et al., Comp. Ther., 1994, 20, 669-673).
- the compounds of the invention may be particularly useful for the prevention and/or treatment of sexual dysfunction in male animals (eg, male erectile dysfunction - MED) and female sexual dysfunction (FSD) in females, such as female sexual arousal disorders (FSAD).
- male animals eg, male erectile dysfunction - MED
- FSD female sexual dysfunction
- FSAD female sexual arousal disorders
- halogen means F, Cl, Br, and I unless otherwise specified. More preferably, the halogen atom is selected from the group consisting of F, Cl and Br.
- C 1 -C 6 alkyl means a straight or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, unless otherwise specified. Butyl, isobutyl, tert-butyl, or the like.
- deuterated means that one or more hydrogens in the compound or group are replaced by deuterium; deuteration may be monosubstituted, disubstituted, polysubstituted or fully substituted.
- deuteration may be monosubstituted, disubstituted, polysubstituted or fully substituted.
- deuterated is used interchangeably with “one or more deuterated”.
- non-deuterated compound means a compound containing a proportion of germanium atoms not higher than the natural helium isotope content (0.015%).
- pharmaceutically acceptable salts include inorganic salts and organic salts.
- a preferred class of salts are the salts of the compounds of the invention with acids.
- Suitable acids for forming salts include, but are not limited to, mineral acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid; formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, Organic acids such as fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid; Amino acids such as amino acid, phenylalanine, aspartic acid, and glutamic acid.
- Salts and other pharmaceutically acceptable amine salts such as methylamine, ethylamine, propylamine, dimethylamine, trimethylamine, diethylamine, triethylamine, tert-butyl
- a base amine salt an ethylenediamine salt, a hydroxyethylamine salt, a dihydroxyethylamine salt, a trihydroxyethylamine salt, and an amine salt formed of morpholine, piperazine, and lysine, respectively.
- solvate refers to a complex of a compound of the invention that is coordinated to a solvent molecule to form a specific ratio.
- Hydrophilate means a complex formed by the coordination of a compound of the invention with water.
- the beneficial effects of the present invention are: (1) the compound of the present invention has excellent inhibitory effect on the serum angiotensin receptor; (2) the chemical conversion of the compound in the organism by the technique of deuteration, The compound has better pharmacokinetic parameter properties.
- the dosage can be changed and a long-acting preparation can be formed to improve the applicability; replacing the hydrogen atom in the compound with hydrazine can increase the drug concentration of the compound in the animal due to its strontium isotope effect, thereby improving the therapeutic effect;
- the substitution of a hydrogen atom in a compound by hydrazine may increase the safety of the compound due to inhibition of certain metabolites.
- Step 1 Synthesis of Compound 2.
- Pt/C 40 mg was added to a hydrazine aqueous solution (4 mL) of 1,2-phenylenediamine, and the mixture was bubbled with hydrogen for 5 minutes, and heated at 100 ° C for 14 hours. After the reaction solution was returned to room temperature, it was diluted with water. Dichloromethane was extracted and dried to give a yellow solid product (yield: 150%).
- Step 3 Synthesis of Compound 6.
- a mixture of compound 4 (95 mg, 545 ⁇ mol) and NaOH (44 mg, 1.09 mmol) was stirred at room temperature for 1 hour, and then, 1,2-dibromoethane (205 mg, 1.09 mmol) was added and the mixture was stirred at room temperature for 1.5 hours. 15 mL of water was poured into the reaction system, extracted with dichloromethane, and dried to give 100 mg of the product as a yellow oil.
- Step 4 Synthesis of Compound 8. An aqueous solution (3 mL) of sodium hydroxide (17 mg, 423 ⁇ mol) was added to a solution of compound 6 (100 mg, 356 ⁇ mol), compound 7 (90 mg, 391 ⁇ mol) in acetone (3 mL), stirred at room temperature overnight, After distilling in dichloromethane, the mixture was applied to a white solid product (yield: 65.4%).
- Step 5 Synthesis of Compound 9. Hydrochloric acid (5 mL, 2 M/L) was added to a solution of compound 8 (100 mg, 230 ⁇ mol) in 1,4-dioxane (5 mL), and stirred at 63 ° C for 2 hours, then returned to room temperature with ethyl acetate The mixture was diluted, extracted and dried to give a white solid product (yield: 51.8%).
- Step 1 Synthesis of Compound 13. Potassium carbonate was added to a solution of compound 11 (1.03 g, 6.17 mmol), Compound 12 (300 mg, 1.23 mmol) in DMF (5 mL), and stirred at 120 ° C overnight. After drying, the product was obtained as a white solid (yield: 380 mg).
- Step 3 Synthesis of Compound 16.
- the reaction was carried out in the same manner as in the step 4 of Example 1 to give 154 mg of product as colorless oil.
- Step 4 Synthesis of Compound 17.
- trifluoroacetic acid (1 mL) was added dropwise to compound 16 (154mg, 291 ⁇ mol) in dichloromethane. After addition was complete the mixture was stirred at rt for 1 h, spin dry, at room temperature was added NH 3 / MeOH (15 mL, 7N) was stirred for 1 hr then dried over dichloromethane, filtered and evaporated.
- Step 1 Synthesis of Compound 19. The reaction was carried out in the same manner as in the step 4 of Example 1 to give 960 mg of product as white solid.
- Step 2 Synthesis of Compound 20.
- the reaction procedure was the same as in the step 2 of Example 2 to give a white solid product (yield: 99%).
- LC-MS (APCI): m / z 232.3 (M + 1) +.
- Step 3 Synthesis of Compound 21.
- Step 4 Synthesis of Compound 22.
- the reaction procedure was the same as in the step 4 of Example 2 to give a white solid product (yield: 42%).
- Step 1 Synthesis of Compound 24.
- a solution of LiAlD 4 (1.12 g, 22.69 mmol) in tetrahydrofuran (THF) (20 mL) was added to a solution of diethyl oxalate (2.6 g, 17.79 mmol) in THF (10 mL) at 0 ° C.
- THF tetrahydrofuran
- 2 mL of water was added, and the filtrate was evaporated to dryness to give a product (yield:
- Step 3 Synthesis of Compound 28.
- the reaction was carried out in the same manner as in the step 3 of Example 2 to give 22 mg of product as a yellow oil.
- LC-MS (APCI): m / z 467.4 (M + 1) +.
- Step 4 Synthesis of Compound 30.
- Potassium carbonate (272 mg, 1.97 mmol) and sodium iodide (197 mg, 1.31 mmol) were added to compound 28 (220 mg, 656 ⁇ mol), compound 29 (302 mg, 1.31 mmol) in acetonitrile (15 mL), and stirred at 80 ° C. After several hours, it was purified by spin-drying to afford 110 mg of product as colorless oil.
- Step 5 Synthesis of Compound 31.
- the reaction procedure was the same as in the step 4 of Example 2 to give a white solid product (yield: 51%).
- Step 1 Synthesis of Compound 33. To a solution of methyl 2-bromoacetate (399 mg, 2.61 mmol), Compound 29 (500 mg, 2.17 mmol) in dichloromethane (15 mL) The product was obtained by spin-drying to give a colorless oily product (yield: 91.4%).
- Step 2 Synthesis of compound 34.
- the reaction was carried out in the same manner as in Step 1 of Example 4 to give 210 mg of product as a colorless oil.
- LC-MS (APCI): m/z 277.3 (M + 1) + .
- Step 3 Synthesis of Compound 36.
- the reaction was carried out in the same manner as in the step 2 of Example 4 to give 250 mg of product as a yellow oil.
- LC-MS (APCI): m / z 355.4 (M + 1) +.
- Step 4 Synthesis of Compound 37.
- the reaction was carried out in the same manner as in the step 4 of Example 4 to give 158 mg of product as a yellow solid.
- Step 5 Synthesis of compound 38.
- the same reaction procedure as in Example 2, Step 4, to give the product as a white solid 1 H NMR (300MHz, CDCl 3 ) ( ⁇ / ppm) 9.31 (brs, 1H), 7.30 (t, J 8.1Hz, 1H), 7.27-7.06 (m, 7H), 4.06 (s, 1H), 3.24-3.22 (m, 4H), 2.78 (s, 1H), 2.77-2.73 (m, 4H).
- LC-MS (APCI): m / z 393.3 (M + 1) +.
- Step 1 Synthesis of Compound 39. Potassium carbonate (261 mg, 1.89 mmol) was added to a solution of methyl 2-bromoacetate (217 mg, 1.42 mmol), Compound 27 (250 mg, 945 ⁇ mol) in acetonitrile (10 mL). The extract was 190 mg of a colorless oily solid, yield: 59.7%.
- LC-MS (APCI): m / z 337.4 (M + 1) +.
- Step 2 Synthesis of Compound 40.
- the reaction procedure was the same as in the step 1 of Example 4 to give 150 mg of product as a colorless oil.
- LC-MS (APCI): m / z 311.3 (M + 1) +.
- Step 3 Synthesis of Compound 41.
- the reaction was carried out in the same manner as in the step 2 of Example 4 to give the product as a yellow oily product (yield: 69.1%).
- LC-MS (APCI): m / z 389.4 (M + 1) +.
- Step 4 Synthesis of Compound 42.
- the reaction was carried out in the same manner as in the step 4 of Example 4 to give a product (yield: 1 H NMR (300MHz, CDCl 3 ) ( ⁇ / ppm) 7.36-7.06 (m, 8H), 5.33 (s, 2H), 4.06 (s, 2H), 3.64-3.58 (m, 2H), 3.21 (s, 4H)), 2.72 (s, 4H), 0.94-0.86 (m 2H), -0.05 (s, 9H).
- LC-MS (APCI): m / z 523.4 (M + 1) +.
- Step 5 Synthesis of compound 43.
- the reaction was carried out in the same manner as in the step 4 of Example 2 to give 50 mg of product as a white solid.
- LC-MS (APCI): m / z 393.3 (M + 1) +.
- Step 1 Synthesis of Compound 44.
- Di-tert-butyl dicarbonate (711 mg, 3.26 mmol) was added to a solution of compound 29 (500 mg, 2.17 mmol), triethylamine (439 mg, 4.34 mmol) in dichloromethane (15 mL). After completion, the mixture was stirred at room temperature for 1 hour, and dried to give a yellow solid product (yield: s.
- LC-MS (APCI): m / z 331.4 (M + 1) +.
- Step 2 Synthesis of compound 45. Hydrochloric acid (217 mg, 2.03 mmol) was added to a solution of compound 44 (670 mg, 2.03 mmol) in EtOAc (5 mL), and stirred at 180 ° C for 30 min. Dichloromethane was extracted and dried to give a pale yellow solid product (yield: 84.6%).
- LC-MS (APCI): m / z 234.3 (M + 1) +.
- Step 3 Synthesis of Compound 46.
- the reaction procedure was the same as in the step 4 of Example 4 to give a product as a yellow solid (230 mg, yield: 58.2%).
- the compounds of the invention were evaluated in a number of tests to determine their biological activity. Some of the compounds tested showed potent inhibitory activity against the serum angiotensin receptor.
- Each of Examples 1-7 was dissolved in DMSO to 0.01 mol/L, and then diluted to 100 ⁇ mol/L with deionized water. Add 10 ⁇ L of the test compound and the radioactive ligand to the reaction tube, and add the final concentration of the test compound and the positive drug to 10 ⁇ mol/L. After incubating for 15 minutes in a 37 ° C water bath, immediately transfer it to an ice bath to terminate it.
- Example number 5HT 2 IC 50 (nM) Example 1 ⁇ 20
- Example 2 ⁇ 20 Example 3 ⁇ 20
- Example 4 ⁇ 20 Example 5 ⁇ 20
- Example 6 ⁇ 20 Example 7 ⁇ 20
- control group 3-[2-[4 -[4-(Trifluoromethyl)phenyl]piperazin-1-yl]B Base]-1H-benzimidazol-2-one;
- Test group Examples 1-13, comparing their pharmacokinetic differences.
- Rats were fed a standard diet and given water. Fasting began 16 hours before the test.
- the drug was dissolved with PEG400 and dimethyl sulfoxide. Blood was collected from the eyelids at a time point of 0.083 hours, 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after administration.
- Rats were briefly anesthetized after inhalation of ether, and 300 ⁇ L of blood samples were collected from the eyelids in test tubes. There was 30 ⁇ L of 1% heparin salt solution in the test tube. The tubes were dried overnight at 60 ° C before use. After the blood sample collection was completed at a later time point, the rats were anesthetized with ether and sacrificed.
- Plasma samples were centrifuged at 5000 rpm for 5 minutes at 4 ° C to separate plasma from red blood cells. Pipette 100 ⁇ L of plasma into a clean plastic centrifuge tube to indicate the name and time point of the compound. Plasma was stored at -80 °C prior to analysis. The concentration of the compound of the invention in plasma was determined by LC-MS/MS. Pharmacokinetic parameters were calculated based on the plasma concentration of each animal at different time points.
- the experimental results show that the compound of the present invention has better pharmacokinetics in animals than the control compound flibanserin, and thus has better pharmacodynamics and therapeutic effects.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种取代的苯并咪唑酮化合物及包含该化合物的组合物,本发明公开了如式(I)所示的取代的苯并咪唑酮化合物以及含有该化合物、或其晶型、药学上可接受的盐、水合物或溶剂合物、立体异构体、前药或同位素变体的药物组合物。本发明公开的取代的苯并咪唑酮化合物及包含该化合物的组合物对5HT2受体具有优异的抑制性,同时具有更好的药代动力学参数特性,能够提高化合物在动物体内的药物浓度,以提高药物疗效和安全性。
Description
本发明属于医药技术领域,尤其涉及一种取代的苯并咪唑酮化合物及包含该化合物的组合物。
血清紧张素(5-羟色胺,5-HT)受体是一种重要的G蛋白-偶联受体。一般认为血清紧张素在与学习和记忆、睡眠、温度调节、情绪、自发活动、疼痛、性和攻击性行为、食欲、神经变性的调节和生物节律有关的过程中发挥作用。正如所料,血清紧张素与疾病生理状况比如焦虑、抑郁症、强迫-强制症、精神***症、***、孤独症、偏头痛、呕吐、酒精中毒和神经变性病症是相联系的。
目前血清紧张素受体被归类为七个亚族(5-HT1至5-HT7)。参见,Hoyer,D.等人,Pharmacol.Rev.,1994,56,157-203。亚族已经被进一步分成亚型。例如,5-HT2受体目前被分成三个亚型:5-HT2a、5-HT2b和5-HT2c。其中,5-HT2受体的三个亚型是与产生两个第二信使:甘油二酯(其活化蛋白激酶C)和肌醇三磷酸酯(其释放胞内存储的Ca2+)的磷脂酶C相连接的。
发明内容
针对以上技术问题,本发明公开了一种取代的苯并咪唑酮化合物及包含该化合物的组合物,其具有更好的血清紧张素受体抑制活性和/或具有更好药效学/药代动力学性能。
对此,本发明采用的技术方案为:
本发明的目的是提供一类新型的具有血清紧张素受体抑制活性的和/或具有更好药效学/药代动力学性能的化合物。
本发明的第一方面中,提供了一种式(I)所示的取代的苯并咪唑酮化合物,或其晶型、药学上可接受的盐、水合物或溶剂化合物。
其中,R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20和R21各自独立地为氢、氘、卤素或三氟甲基;
X为C、N;
附加条件是R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20和R21中至少一个是氘。
氘在药物分子中的形状和体积与氢基本上相同,如果药物分子中氢被选择性替换为氘,氘代药物一般还会保留原来的生物活性和选择性。同时发明人经过实验证实,碳氘键的结合比碳氢键的结合更稳定,可直接影响一些药物的吸收、分布、代谢和***等属性,从而提高药物的疗效、安全性和耐受性。
在另一优选例中,氘在各氘代位置的氘同位素含量至少是大于天然氘同位素含量(0.015%),较佳地大于30%,更佳地大于50%,更佳地大于75%,更佳地大于95%,更佳地大于99%。
具体地说,在本发明中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20和R21各氘代位置中氘同位素含量至少是5%,较佳地大于10%,更佳地大于15%,更佳地大于20%,更佳地大于25%,更佳地大于30%,更佳地大于35%,更佳地大于40%,更佳地大于45%,更佳地大于50%,更佳地大于55%,更佳地大于60%,更佳地大于65%,更佳地大于70%,更佳地大于75%,更佳地大于80%,更佳地大于85%,更佳地大于90%,更佳地大于95%,更佳地大于99%。
在另一优选例中,式(I)中化合物的R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20和R21,至少其中一个R含氘,更佳地两个R含氘,更佳地三个R含氘,更佳地四个R含氘,更佳地五个R含氘,更佳地六个R含氘,更佳地七个R含氘,更佳地八个R含氘,更佳地九个R含氘,更佳地十个R含氘,更佳地十一个R含氘,更佳地十二个R含氘,更佳地十三个R含氘,更佳地十四个R含氘,更佳地十五个R含氘,更佳地十六个R含氘,更佳地十七个R含氘,更佳地十八个R含氘,更佳地十九个R含氘,更佳地二十个R含氘,更佳地二十一个R含氘。
在另一优选例中,R18是三氟甲基。
在另一优选例中,R1、R2、R3和R4各自独立地为氘或氢。
在另一优选例中,R5、R6、R7和R8各自独立地为氘或氢。
在另一优选例中,R9、R10、R11、R12、R13、R14、R15和R16各自独立地为氘或氢。
在另一优选例中,R17、R19、R20和R21各自独立地为氘或氢。
在另一优选例中,其特征在于,R1、R2、R3、R4是氘。
在另一优选例中,其特征在于,R5、R6、R7、R8是氘。
在另一优选例中,其特征在于,R9、R10、R11、R12、R13、R14、R15、R16是氘。
在另一优选例中,R17、R19、R20、R21是氘。
在另一优选例中,所述化合物选自下组化合物或其药学上可接受的盐:
在另一优选例中,所述化合物不包括非氘代化合物。
在另一优选例中,所述的非氘代化合物为3-[2-[4-[4-(三氟甲基)苯基]哌嗪-1-基]乙基]-1H-苯并咪唑-2-酮。
在本发明的第二方面中,提供了一种制备药物组合物的方法,包括步骤:将药学上可接受的载体与本发明第一方面中所述的化合物,或其晶型、药学上可接受的盐、水合物或溶剂合物进行混合,从而形成药物组合物。
在本发明的第三方面中,提供了一种药物组合物,它含有药学上可接受的载体和本发明第一方面中所述的化合物,或其晶型、药学上可接受的盐、水合物或溶剂合物。
在另一优选例中,所述的药物组合物为注射剂、囊剂、片剂、丸剂、散剂或颗粒剂。
本发明的化合物可以与其它药物联合给药,比如载脂蛋白-B/MTP抑制剂、MCR-4激动剂、CCK-A激动剂、单胺再摄取抑制剂、拟交感神经药、β3肾上腺素能受体激动剂、多巴胺激动剂、促黑素细胞激素受体类似物、***素1受体拮抗剂、黑色素浓缩激素拮抗药、瘦激素、瘦激素类似物、瘦激素受体激动剂、甘丙肽拮抗剂、脂肪酶抑制剂、铃蟾肽激动剂、神经肽-Y拮抗剂、拟甲状腺素药、脱氢异雄甾酮或其类似物、糖皮质激素受体激动剂或拮抗剂、阿立新(orexin)受体拮抗剂、尿皮质素结合蛋白拮抗剂、胰高血糖素样肽-1受体激动剂、睫状神经营养因子、AGRPs(人野灰相关蛋白质)、生长素释放肽受体拮抗剂、组胺3受体拮抗剂或反向激动剂、神经调节肽U受体
激动剂等。
联合治疗可以以下方式给药:(1)单一的药物组合物,包含本发明的化合物,至少一种如上所述的其它药剂以及药学可接受的赋形剂、稀释剂或载体;或(2)两种分开的药物组合物,包含式(I)的化合物和药学可接受的赋形剂、稀释剂或载体。药物组合物可同时或依次和以任何顺序给药。
在本发明的另一方面,提供了一种消费者使用的药物试剂盒,用于治疗动物中5-HT2受体-介导的疾病、状况或障碍。该试剂盒包含a)包含本发明化合物的适宜剂型;和b)描述使用该剂型治疗或预防5-HT2受体-介导的疾病、状况或障碍的方法的说明书。
本发明的另一实施方案是一种药物试剂盒,包含:a)第一种剂型,包含(i)本发明的化合物和(ii)药学可接受的载体、赋形剂或稀释剂;b)第二种剂型,包含(i)一种如上所述的其它药剂,和(ii)药学可接受的载体、赋形剂或稀释剂;和c)一种容器。
本发明的另一个方面是一种治疗雌性动物性功能障碍(FSD)的方法,包含给予需要该治疗的雌性动物治疗有效量的本发明化合物的步骤。该方法可更进一步包括给予一或多种另外的用于治疗FSD的活性药物。另外的活性剂可以选自:(1)***受体蛋白调节剂、***激动剂、***拮抗剂或其组合;(2)睾酮替代剂、睾酮、二氢睾酮、脱氢异雄甾酮、睾酮植入物或其组合;(3)***、***和甲羟孕酮或醋酸甲羟孕酮的组合,或***和甲基睾酮激素代替治疗剂;(4)一或多种多巴胺能药;(5)一或多种NPY(神经肽Y)抑制剂;(6)一或多种黑皮质素受体激动剂或调节剂或黑皮质素增强剂;(7)一或多种中性内肽酶(NEP)抑制剂;(8)一或多种磷酸二酯酶(PDE)抑制剂;和(9)一或多种铃蟾肽受体拮抗剂或调节剂。FSD治疗包括雌性动物性唤起障碍(FSAD)、雌性动物性高潮障碍(FOD)、机能减退的***障碍(HSDD)或***疼痛障碍。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一累述。
本发明还包括同位素标记的化合物,等同于原始化合物在此公开。可以列为本发明的化合物同位素的例子包括氢,碳,氮,氧,磷,硫,氟和氯同位素,分别如2H,3H,13C,14C,15N,17O,18O,31P,32P,35S,18F以及36Cl。本发明中的化合物,或对映体,非对映体,异构体,或药学上可接受的盐或溶剂化物,其中含有上述化合物的同位素或其他其他同位素原子都在本发明的范围之内。本发明中某些同位素标记化合物,例如3H和14C的放射性同位素也在其中,在药物和底物的组织分布实验中是有用的。氚,即3H和碳-14,即14C,它们的制备和检测比较容易,是同位素中的首选。此外,较重同位素取代如氘,即2H,由于其很好的代谢稳定性在某些疗法中有优势,
例如在体内增加半衰期或减少用量,因此,在某些情况下可以优先考虑。同位素标记的化合物可以用一般的方法,通过用易得的同位素标记试剂替换为非同位素的试剂,用示例中的方案可以制备。
本发明化合物可有效用作5HT2部分激动剂或拮抗剂;因此,本发明的另一个实施方案是一种药物组合物,包括治疗有效量的本发明化合物和药物可接受的赋形剂、稀释剂或载体。
典型的制剂是通过本发明化合物与载体、稀释剂或赋形剂进行混合制备的。适宜的载体、稀释剂和赋形剂是本领域技术人员所熟知的,包括物质比如碳水化合物、石蜡、水溶性的和/或可膨胀的聚合物、亲水的或疏水性的物质、明胶、油剂、溶剂、水等。所使用的具体载体、稀释剂或赋形剂将取决于应用本发明化合物的方式和目的。溶剂通常选自以本领域技术人员认为对所给药的哺乳动物安全的的溶剂。通常,安全的溶剂是无毒的含水溶剂比如水及其它在水中可溶的或可混溶的无毒溶剂。适宜的含水溶剂包括水、乙醇、丙二醇、聚乙二醇(例如,PEG400、PEG300)等及其混合物。制剂还可以包括一或多种缓冲液、稳定剂、表面活性剂、润湿剂、润滑剂、乳化剂、助悬剂、防腐剂、抗氧化剂、避光剂、助流剂、过程助剂、着色剂、甜味剂、香料、调味剂及其它已知的添加剂,以提供药物(即,本发明化合物或它们的药物组合物)精美的外观,或有助于药剂(即,药物)的制造。
可使用常规的溶解和混合过程制备制剂。例如,可在如上所述的一或多种赋形剂的存在下,将批量药物物质(即,本发明化合物或该化合物的稳定化形式(例如,与环糊精衍生物或其它已知的复合试剂的复合物))溶于适宜的溶剂中。可将本发明化合物典型地配制成药物剂型,以提供容易控制的药物剂量并为患者提供精致的和容易使用的产物。
用于给药的药物组合物(或制剂)可以被以各种方法包装,取决于所使用的给药方法。通常,分配的物品包括可将药物制剂以适当的形式放置于其中的容器。适宜的容器是本领域技术人员所熟知的,包括材料比如瓶(塑料的和玻璃的)、小袋、安瓿、塑料袋、金属圆筒等。容器还可以包括防干扰的装配件以防止轻率地使用包装的内容物。此外,在容器上加标签以记载容器中的内容物。标签还可以包括适当的警告。
本发明更进一步为需要这样的治疗的动物中提供了治疗5HT2受体-介导的疾病、状况或障碍的方法,包括给予动物治疗有效量的本发明化合物或包含有效量的本发明化合物和药学可接受的赋形剂、稀释剂或载体的药物组合物。该方法可特别有用于治疗5HT2受体-介导的疾病、状况或障碍。优选地,本发明的化合物作为5HT2受体地部分激动剂。更优选地,本发明的化合物作为5HT2受体地部分激动剂并且作用5HT2受
体地拮抗剂。
优选地,5HT2受体-介导的疾病、状况或障碍选自:体重减轻(例如、在热量摄入下降)、肥胖、贪食症、经前期综合征或迟黄体期综合症、抑郁症、非典型性抑郁症、躁狂抑郁性精神病、精神病、精神***症、偏头痛、酒精中毒、烟草滥用、恐慌症、焦虑、创伤后综合征、记忆丧失、老年痴呆、社会恐怖症、注意缺陷障碍伴多动症、破坏性行为障碍、冲动控制障碍、临界人格障碍、强迫性强制障碍、慢性疲乏综合征、雄性性功能障碍(例如,早泄和***困难)、雌性性功能障碍、神经性厌食症、睡眠障碍(例如,睡眠呼吸暂停)、孤独症、癫痫发作、癫痫、缄默症、脊髓损伤、中枢神经***损伤(例如,外伤、中风、神经退行性疾病或有毒或传染性CNS疾病(例如,脑炎或脑膜炎))、心血管疾病(例如,血栓形成)、胃肠道病症(例如,胃肠运动性功能障碍)、尿崩症和II型糖尿病。相应地,这里描述的本发明化合物可有效用于治疗或预防5-HT2受体-介导的疾病、状况或障碍。因此,本发明化合物(包括组合物和其中所使用的方法)可用于制造用于这里所描述的治疗应用的药物。
本发明化合物可以以每天约0.7毫克到约7,000毫克的剂量水平对患者给药。对于正常体重约70千克的成年人,典型地每公斤体重约0.01毫克到约100毫克的剂量是足够的。然而,通常的剂量范围可根据所要治疗患者的年龄和重量、给药的途径、给予的特定的化合物等等进行一些改变。对于特定患者的剂量范围和最佳剂量的确定,是在得益于本公开的本领域普通技术人员的能力范围之内的。还应注意本发明的化合物可以缓释释放、控制释放和迟延释放制剂的形式使用,其形式是普通技术人员所熟知的。
本发明的化合物还可以与其它用于治疗本文中所描述的疾病/状况的药物结合使用。因此,还提供了包括给予与其它药物组合的本发明化合物的治疗方法。可与本发明的化合物联用的适宜的药物包括抗肥胖剂比如载脂蛋白-B分泌/微粒体甘油三酸酯转移蛋白(apo-B/MTP)抑制剂,MCR-4激动剂、缩胆囊肽-A(CKK-A)激动剂、单胺再摄取抑制剂(比如***)、拟交感神经药剂、β3肾上腺素能受体激动剂、多巴胺激动剂(比如溴麦角环肽)、促黑素细胞激素受体类似物、***素1受体拮抗剂、黑色素浓缩激素拮抗药、瘦激素(OB蛋白)、瘦激素类似物、瘦激素受体激动剂、甘丙肽拮抗剂、脂肪酶抑制剂(比如tetrahydrolipstatin,即奥利司他)、减食欲剂(比如A铃蟾肽激动剂)、神经肽-Y拮抗剂、拟甲状腺素药、脱氢异雄甾酮或它们的类似物、糖皮质激素受体激动剂或拮抗剂、阿立新受体拮抗剂、尿皮质素结合蛋白拮抗剂、胰高血糖素样肽-1受体激动剂、睫状神经营养因子(比如AxokineTM,Regeneron Pharmaceuticals,Inc.,Tarrytown,NY和Procter&Gamble Company,Cincinnati,OH)、人野灰相关蛋白质
(AGRP)、生长素释放肽受体拮抗剂、组胺3受体拮抗剂或反向激动剂、神经调节肽铀受体激动剂。其它抗肥胖药剂,包括在下文所列出的优选药剂是为大家所熟知的,或按照本公开的教导对普通技术人员是很明显的。
尤其优选的抗肥胖药剂选自:奥利司他、***、溴麦角环肽、麻黄素、瘦激素和假麻黄碱。优选地,本发明化合物以及联合治疗应结合锻炼和合理的饮食。
在联合用药、药物组合物和本发明的方法中所使用的代表性的抗肥胖药剂可以使用普通技术人员所熟知的方法制备,例如,***可以按照美国专利US 4,929,629中所述制备;溴麦角环肽可以按照美国专利U.S.3,752,814和3,752,888中所述方法制备;而奥利司他可按照美国专利U.S.5,274,143;5,420,305;5,540,917;和5,643,874中所述方法制备。上述所有引用的美国专利在此引入作为参考。
其它药物(例如,抗肥胖药剂)的剂量通常还将还取决于许多因素,包括要被治疗的患者的健康状况,所需要治疗的程度,并存治疗的性质和种类(如果有的话),以及治疗的次数和目标效果的性质。通常,抗肥胖药剂的剂量范围为每人每公斤体重每天约0.001毫克到约100毫克,优选每人每公斤体重每天约0.1毫克到约10毫克。然而,通常的剂量范围还可根据要进行治疗的患者的年龄和重量、给药的途径、给予的特定的抗肥胖药剂等等进行一些改变。对于特定患者的剂量范围和最佳剂量的确定,也是在得益于本公开的本领域普通技术人员的能力范围之内的。
在本发明的另一个实施方案中,发现本发明的化合物可用于治疗性功能障碍。性功能障碍(SD)是一种值得注意的临床问题,雄性和雌性动物都可能被波及。导致SD的原因既可能是器质性的也可能是心理上的。器质方面的SD典型地由潜在的血管疾病比如与高血压或糖尿病有关的血管疾病,由处方药物和/或由精神性疾病比如抑郁症所引起。生理的因素包括恐惧、行为焦虑和人际冲突。SD损害性行为、消弱自尊和破坏人际关系,由此引起个人的痛苦。在临床中,SD障碍被分成雌性性机能(FSD)障碍和雄性性功能障碍(MSD)。FSD可明确定义为妇女对性表现感到满意的困难或无能。MSD通常与***机能障碍有关,亦称雄性***机能障碍(MED)(Benet等人,Comp.Ther.,1994,20,669-673)。
本发明的化合物可特别有益于预防和/或治疗雄性动物中的性功能障碍(例如雄性***功能障碍-MED)和雌性动物中的-雌性性功能障碍(FSD),例如雌性动物性唤起障碍(FSAD)。
本文中,如无特别说明,“卤素”指F、Cl、Br、和I。更佳地,卤原子选自F、Cl和Br。
本文中,如无特别说明,“C1-C6烷基”是指包括1-6个碳原子的直链或支链的烷基,
例如甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基、或类似基团。
本文中,如无特别说明,“氘代”指化合物或基团中的一个或多个氢被氘所取代;氘代可以是一取代、二取代、多取代或全取代。术语“一个或多个氘代的”与“一次或多次氘代”可互换使用。
本文中,如无特别说明,“非氘代的化合物”是指含氘原子比例不高于天然氘同位素含量(0.015%)的化合物。
本发明中,药学上可接受的盐包括无机盐和有机盐。一类优选的盐是本发明化合物与酸形成的盐。适合形成盐的酸包括但并不限于:盐酸、氢溴酸、氢氟酸、硫酸、硝酸、磷酸等无机酸;甲酸、乙酸、三氟乙酸、丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、苦味酸、苯甲酸、甲磺酸、乙磺酸、对甲苯磺酸、苯磺酸、萘磺酸等有机酸;以及脯氨酸、苯丙氨酸、天冬氨酸、谷氨酸等氨基酸。另一类优选的盐是本发明化合物与碱形成的盐,例如碱金属盐(例如钠盐或钾盐)、碱土金属盐(例如镁盐或钙盐)、铵盐(如低级的烷醇铵盐以及其它药学上可接受的胺盐),例如甲胺盐、乙胺盐、丙胺盐、二甲基胺盐、三甲基胺盐、二乙基胺盐、三乙基胺盐、叔丁基胺盐、乙二胺盐、羟乙胺盐、二羟乙胺盐、三羟乙胺盐,以及分别由吗啉、哌嗪、赖氨酸形成的胺盐。
术语“溶剂合物”指本发明化合物与溶剂分子配位形成特定比例的配合物。“水合物”是指本发明化合物与水进行配位形成的配合物。
与现有技术相比,本发明的有益效果为:(1)本发明化合物对血清紧张素受体具有优异的抑制性;(2)通过氘化这一技术改变化合物在生物体中的代谢,使化合物具有更好的药代动力学参数特性。在这种情况下,可以改变剂量并形成长效制剂,改善适用性;用氘取代化合物中的氢原子,由于其氘同位素效应,能够提高化合物在动物体内的药物浓度,以提高药物疗效;用氘取代化合物中的氢原子,由于某些代谢产物被抑制,可能提高化合物的安全性。
下面更具体地描述本发明式(I)结构化合物的制备方法,但这些具体方法不对本发明构成任何限制。本发明化合物还可以任选将在本说明书中描述的或本领域已知的各种合成方法组合起来而方便地制得,这样的组合可由本发明所属领域的技术人员容易地进行。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。除非另外说明,否则份数和百分比为重量份
和重量百分比。
实施例1. 4,5,6,7-d4-3-[2-[4-[4-(三氟甲基)苯基]哌嗪-1-基]乙基]-1H-苯并咪唑-2-酮
(化合物9)的合成
步骤1:化合物2的合成。将Pt/C(40mg)加入至1,2-苯二胺的氘水溶液(4mL)中,用氢气鼓泡5分钟,在100℃下加热14小时,待反应液恢复至室温后,用水稀释,二氯甲烷萃取,旋干得到黄色固体产物150mg,收率为72.5%。1H NMR(300MHz,DMSO-d6)(δ/ppm)4.39(s,4H);LC-MS(APCI):m/z=113.2(M+1)+。
步骤2:化合物4的合成。将乙酰乙酸乙酯加入至化合物2(150mg,1.34mmol)与KOH(3mg,53μmol)的甲苯溶液(4mL)中,回流14小时,旋干过柱得无色油状产物95mg,收率为39.9%。1H NMR(300MHz,DMSO-d6)(δ/ppm)10.97(s,1H),5.34(d,J=1.5Hz,1H),5.13(d,J=0.6Hz,1H),2.14(s,3H);LC-MS(APCI):m/z=179.2(M+1)+。
步骤3:化合物6的合成。将化合物4(95mg,545μmol)与NaOH(44mg,1.09mmol)的混合物在室温下搅拌1小时,加入1,2-二溴乙烷(205mg,1.09mmol),继续在室温下搅拌1.5小时。将15mL水倒入反应体系中,用二氯甲烷萃取,旋干过柱得黄色油状产物100mg,收率为65.4%。1H NMR(300MHz,DMSO-d6)(δ/ppm)5.38(d,J=1.5Hz,1H),5.23(d,J=0.9Hz,1H),5.35(s,1H),5.20(s,1H),4.30(t,J=7.2Hz,2H),3.68(t,J=6.9Hz,4H),2.25(s,3H);LC-MS(APCI):m/z=285.2(M+1)+。
步骤4:化合物8的合成。将氢氧化钠(17mg,423μmol)的水溶液(3mL)加入至化合物6(100mg,356μmol)、化合物7(90mg,391μmol)的丙酮溶液(3mL)中,在室温下搅拌过夜,旋干丙酮,溶于二氯甲烷,萃取后旋干过柱得黄色固体产物100mg,收率为65.4%。1H NMR(300MHz,CDCl3)(δ/ppm)7.35(t,J=7.8Hz,1H),7.10-7.05(m,3H),5.35(s,1H),5.20(s,1H),4.07(t,J=6.6Hz,2H),3.23(t,J=5.1Hz,4H),2.81-2.72(m,6H);LC-MS(APCI):m/z=435..3(M+1)+。
步骤5:化合物9的合成。将盐酸(5mL,2M/L)加入至化合物8(100mg,230μmol)的1,4-二氧六环溶液(5mL)中,在63℃下搅拌2小时后,恢复至室温,用乙酸乙酯稀
释,萃取后旋干纯化得白色固体产物47mg,收率为51.8%。1H NMR(300MHz,DMSO-d6)(δ/ppm)10.82(s,1H),7.40(t,J=7.8Hz,1H),7.20(d,J=7.8Hz,1H),7.18(s,1H),7.05(d,J=7.5Hz,1H),3.94(t,J=6.6Hz,2H),3.18-3.15(m,4H),2.65-2.59(m,6H);LC-MS(APCI):m/z=395.3(M+1)+。
实施例2. 3-[2-[4-[4-(三氟甲基)苯基]2,2,3,3,5,5,6,6-d8-哌嗪-1-基]乙基]-1H-苯并咪
唑-2-酮(化合物17)的合成
步骤1:化合物13的合成。将碳酸钾加入至化合物11(1.03g,6.17mmol)、化合物12(300mg,1.23mmol)的DMF溶液(5mL)中,在120℃下搅拌过夜,倒入50mL水,用乙酸乙酯萃取,旋干后得白色固体产物380mg,收率为96.9%。1H NMR(300MHz,DMSO-d6)(δ/ppm)7.32(t,J=1.8Hz,1H),7.16-7.14(m,2H),2.35(br s,1H);LC-MS(APCI):m/z=317.2(M+1)+。
步骤2:化合物14的合成。将Pd/C(35mg)加入至化合物13(350mg,1.1mmol)的甲醇溶液(10mL)中,在氢气氛围下室温搅拌2小时,过滤,旋干滤液得白色固体产物250mg,收率为71%。1H NMR(300MHz,DMSO-d6)(δ/ppm)8.77(s,2H),7.45(t,J=8.1Hz,,1H),7.30-7.25(m,2H),7.15(d,J=7.5Hz,1H);LC-MS(APCI):m/z=238.3(M+1)+。
步骤3:化合物16的合成。反应步骤与实施例1步骤4相同,得到无色油状产物154mg,收率为54.2%。1H NMR(300MHz,CDCl3)(δ/ppm)7.35(t,J=7.5Hz,1H),7.28-7.04(m,7H),5.34(s,2H),4.08(t,J=6.6Hz,2H),3.62(t,J=7.8Hz,2H),0.93(t,J=8.4Hz,2H),0.05(s,9H);LC-MS(APCI):m/z=529.4(M+1)+。
步骤4:化合物17的合成。0℃下,将三氟乙酸(1mL)逐滴加入至化合物16(154mg,291μmol)的二氯甲烷溶液中,滴加完毕后,室温下搅拌1小时,旋干,在室温下加入NH3/MeOH(15mL,7N)搅拌1小时,旋干溶于二氯甲烷,过滤,旋干滤液,过柱得白色固体产物90mg,收率为77.6%。1H NMR(300MHz,DMSO-d6)(δ/ppm)9.34(s,1H),7.35(t,J=7.5Hz,1H),7.13-7.02(m,7H),4.08(t,J=6.6Hz,2H),2.80(t,J=6.6Hz,2H);LC-MS(APCI):m/z=399.3(M+1)+。
实施例3. 3-[2-[4-[4-(三氟甲基)-6-d-苯基哌嗪-1-基]乙基]-1H-苯并咪唑-2-酮(化合
物22)的合成
步骤1:化合物19的合成。反应步骤与实施例1步骤4相同,得到白色固体产物960mg,收率为75.6%。1H NMR(300MHz,DMSO-d6)(δ/ppm)7.32(s,1H),7.16-7.15(m,2H),3.16(t,J=4.5,4H),2.80(t,J=4.5Hz,4H);LC-MS(APCI):m/z=309.1(M+1)+。
步骤2:化合物20的合成。反应步骤与实施例2步骤2相同,得到白色固体产物200mg,收率为99%。LC-MS(APCI):m/z=232.3(M+1)+。
步骤3:化合物21的合成。反应步骤与实施例2步骤3相同,得到无色油状产物90mg,收率为32%。1H NMR(300MHz,DMSO-d6)(δ/ppm)7.26-7.18(m,3H)7.11-7.04(m,4H),5.24(s,2H),4.01(t,J=6.3Hz,2H),3.50(t,J=7.8Hz,2H),3.12(t,J=4.5Hz,2H),2.68-2.57(m,6H),0.15(s,9H);LC-MS(APCI):m/z=522.4(M+1)+。
步骤4:化合物22的合成。反应步骤与实施例2步骤4相同,得到白色固体产物42mg,收率为62.2%。1H NMR(300MHz,DMSO-d6)(δ/ppm)9.71(s,1H),7.12-7.03(m,7H),4.08(t,J=6.9Hz,2H),3.22(t,J=4.8Hz,4H),2.82-2.72(m,6H);LC-MS(APCI):m/z=392.3(M+1)+。
实施例4. 3-[2-[4-[4-(三氟甲基苯基哌嗪-1-基]-1,1,2,2-d4-乙基]-1H-苯并咪唑-2-酮
(化合物31)的合成
步骤1:化合物24的合成。将LiAlD4(1.12g,22.69mmol)的四氢呋喃(THF)溶液(20mL)在0℃下加入至草酸二乙酯(2.6g,17.79mmol)的THF溶液(10mL)中,滴加完后,在80℃下搅拌3小时,加入2mL水,过滤旋干滤液得到无色油状产物700mg,收率为59.3%。
步骤2:化合物26的合成。将吡啶加入至化合物24(700mg,1059mmol)、化合物25(TsCl,4.64g,24.36mmol)的50mL二氯甲烷溶液中,室温下搅拌过夜,水洗后过柱得到黄色固体产物400mg,收率为10.1%。1H NMR(300MHz,DMSO-d6)(δ/ppm)7.74(d,J=8.4Hz,4H),7.35(d,J=8.4Hz,4H),2.46(s,6H);LC-MS(APCI):m/z=375.2(M+1)+。
步骤3:化合物28的合成。反应步骤与实施例2步骤3相同,得到黄色油状产物22mg,收率为89.8%。LC-MS(APCI):m/z=467.4(M+1)+。
步骤4:化合物30的合成。将碳酸钾(272mg,1.97mmol)、碘化钠(197mg,1.31mmol)加入至化合物28(220mg,656μmol)、化合物29(302mg,1.31mmol)的乙腈溶液(15mL)中,80℃下搅拌16小时,旋干过柱纯化得到无色油状产物110mg,收率为32.0%。1H NMR(300MHz,DMSO-d6)(δ/ppm)7.34(t,J=4.8Hz,1H),7.20-7.18(m,1H),7.14-7.01(m,7H),5.33(s,2H),3.61(t,J=5.1Hz,2H),3.21(t,J=3.0Hz,4H),2.72(t,J=3Hz,4H),0.93-0.90(m,2H),-0.05(s,9H);LC-MS(APCI):m/z=525.4(M+1)+。
步骤5:化合物31的合成。反应步骤与实施例2步骤4相同,得到白色固体产物51mg,收率为61.4%。1H NMR(300MHz,DMSO-d6)(δ/ppm)9.71(s,1H),7.12-7.03(m,7H),4.08(t,J=6.9Hz,2H),3.22(t,J=4.8Hz,4H),2.82-2.72(m,6H);LC-MS(APCI):m/z=395.3(M+1)+。
实施例5. 3-[2-[4-[4-(三氟甲基苯基哌嗪-1-基]-1,1-d2-乙基]-1H-苯并咪唑-2-酮(化
合物38)的合成
步骤1:化合物33的合成。将三乙胺(440mg,4.34mmol)加入至2-溴乙酸甲酯(399
mg,2.61mmol)、化合物29(500mg,2.17mmol)的二氯甲烷溶液(15mL)中,室温下搅拌2小时,旋干过柱得无色油状产物600mg,收率为91.4%。1H NMR(300MHz,CDCl3)(δ/ppm)7.35(t,J=4.8Hz,1H),7.11-7.05(m,3H),3.75(s,3H),3.31-3.29(m,6H),2.76(t,J=3.6Hz,4H);LC-MS(APCI):m/z=303.4(M+1)+。
步骤2:化合物34的合成。反应步骤与实施例4步骤1相同,得到无色油状产物210mg,收率为76.1%。1H NMR(300MHz,CDCl3)(δ/ppm)7.37(t,J=6Hz,1H),7.13-7.07(m,3H),3.27(t,J=3.6Hz,4H),2.70(t,J=3.9Hz,4H),2.63(s,2H);LC-MS(APCI):m/z=277.3(M+1)+。
步骤3:化合物36的合成。反应步骤与实施例4步骤2相同,得到黄色油状产物250mg,收率为98.0%。LC-MS(APCI):m/z=355.4(M+1)+。
步骤4:化合物37的合成。反应步骤与实施例4步骤4相同,得到黄色固体产物158mg,收率为42.8%。1H NMR(300MHz,CDCl3)(δ/ppm)7.34(t,J=7.8Hz,1H),7.21-7.03(m,7H),5.33(s,2H),4.06(s,1H),3.61(t,J=8.1Hz,2H),3.23-3.18(m,4H)),2.76-2.70(m,5H),0.91(t,J=8.1Hz,2H),0.05(s,9H);LC-MS(APCI):m/z=523.4(M+1)+。
步骤5:化合物38的合成。反应步骤与实施例2步骤4相同,得到白色固体产物1H NMR(300MHz,CDCl3)(δ/ppm)9.31(brs,1H),7.30(t,J=8.1Hz,1H),7.27-7.06(m,7H),4.06(s,1H),3.24-3.22(m,4H),2.78(s,1H),2.77-2.73(m,4H)。LC-MS(APCI):m/z=393.3(M+1)+。
实施例6. 3-[2-[4-[4-(三氟甲基苯基哌嗪-1-基]-2,2-d2-乙基]-1H-苯并咪唑-2-酮(化
合物43)的合成
步骤1:化合物39的合成。将碳酸钾(261mg,1.89mmol)加入至2-溴乙酸甲酯(217mg,1.42mmol)、化合物27(250mg,945μmol)的乙腈溶液(10mL)中,室温下搅拌12小
时,加入二氯甲烷,萃取得无色油状固体190mg,收率为59.7%。LC-MS(APCI):m/z=337.4(M+1)+。
步骤2:化合物40的合成。反应步骤与实施例4步骤1相同,得到无色油状产物150mg,收率为90.1%。LC-MS(APCI):m/z=311.3(M+1)+。
步骤3:化合物41的合成。反应步骤与实施例4步骤2相同,得到黄色油状产物130mg,收率为69.1%。LC-MS(APCI):m/z=389.4(M+1)+。
步骤4:化合物42的合成。反应步骤与实施例4步骤4相同,得到黄色固体产物120mg,收率为68.6%。1H NMR(300MHz,CDCl3)(δ/ppm)7.36-7.06(m,8H),5.33(s,2H),4.06(s,2H),3.64-3.58(m,2H),3.21(s,4H)),2.72(s,4H),0.94-0.86(m 2H),-0.05(s,9H)。LC-MS(APCI):m/z=523.4(M+1)+。
步骤5:化合物43的合成。反应步骤与实施例2步骤4相同,得到白色固体产物50mg,收率为55.6%。1H NMR(300MHz,CDCl3)(δ/ppm)9.18(s,1H),7.33(t,J=7.5Hz,1H),7.11-7.02(m,7H),4.12(t,J=7.2Hz,2H),3.22(t,J=4.8Hz,4H)),2.73(t,J=4.8Hz,,4H)。LC-MS(APCI):m/z=393.3(M+1)+。
实施例7. 3-[2-[4-[4-(三氟甲基-2,4,6-d3-苯基哌嗪-1-基]乙基]-1H-苯并咪唑-2-酮(化
合物47)的合成
步骤1:化合物44的合成。在0℃下,将二碳酸二叔丁酯(711mg,3.26mmol)加入至化合物29(500mg,2.17mmol)、三乙胺(439mg,4.34mmol)的二氯甲烷溶液(15mL)中,滴加完成后,室温下搅拌1小时,旋干过柱得黄色固体产物680mg,收率为93.4%。LC-MS(APCI):m/z=331.4(M+1)+。
步骤2:化合物45的合成。在0℃下,将盐酸(217mg,2.03mmol)加入至化合物44(670mg,2.03mmol)的氘水溶液(5mL)中,在180℃下搅拌30分钟后,用碳酸氢钠溶液调节至中性,二氯甲烷萃取,旋干得黄色固体产物400mg,收率为84.6%。
LC-MS(APCI):m/z=234.3(M+1)+。
步骤3:化合物46的合成。反应步骤与实施例4步骤4相同,得到黄色固体产物230mg,收率为58.2%。1H NMR(300MHz,DMSO-d6)(δ/ppm)7.38(s,1H),7.26-7.18(m,1H),7.09-7.04(m,3H),5.24(s,2H),4.01(t,J=6.9Hz,2H),3.50(t,J=7.8Hz,2H),3.12(t,J=4.8Hz,4H)),2.67-2.57(m,6H),0.77(t,J=7.8Hz,2H);LC-MS(APCI):m/z=524.5(M+1)+。
化合物的生物评价
对本发明的化合物在多个测试中进行评价以确定它们的生物学活性。一些测试的化合物对血清紧张素受体显示出强效的抑制活性。
(1)5HT2受体抑制作用评价
实施例1-7均用DMSO溶解至0.01mol/L,然后用去离子水稀释至100μmol/L。将待测化合物与放射性配基各10μL及80μL受体蛋白加入反应试管中,使受试化合物及阳性药物终浓度均为10μmol/L,37℃水浴孵育15分钟后,即刻移至冰浴终止其反应;在Millipore细胞样品收集器上,经过GF/B玻璃纤维滤纸快速抽滤,并用洗脱液(50mM Tris-HCl,PH 7.7)3ml洗涤3次,用微波炉8~9分钟烘干,将滤纸移入0.5mL离心管中,加入500μL脂溶性闪烁液。避光静置30分钟以上,计数测定放射性强度。计算各化合物对同位素配基结合的抑制百分率,抑制率高90%的化合物进行一系列浓度的受体结合试验,确定半数抑制量(IC50,抑制50%阳性对照药物与受体结合所需化合物浓度)。每浓度测定两副管,每个化合物进行两次独立试验。结果如表1所示,实施例1-7对5HT2具有高选择性活性。
表1实施例化合物对5HT2受体抑制作用评价
实施例编号 | 5HT2IC50(nM) |
实施例1 | <20 |
实施例2 | <20 |
实施例3 | <20 |
实施例4 | <20 |
实施例5 | <20 |
实施例6 | <20 |
实施例7 | <20 |
(2)大鼠中的药代动力学评价
8只雄性Sprague-Dawley大鼠,7-8周龄,体重约210g,分成2组,每组4只,单次口服给予5mg/kg剂量的(a)对照组:3-[2-[4-[4-(三氟甲基)苯基]哌嗪-1-基]乙
基]-1H-苯并咪唑-2-酮;(b)试验组:实施例1-13,比较其药代动力学差异。
大鼠采用标准饲料饲养,给予水。试验前16小时开始禁食。药物用PEG400和二甲亚砜溶解。眼眶采血,采血的时间点为给药后0.083小时,0.25小时、0.5小时、1小时、2小时、4小时、6小时、8小时、12小时和24小时。
大鼠吸入***后短暂麻醉,眼眶采集300μL血样于试管。试管内有30μL1%肝素盐溶液。使用前,试管于60℃烘干过夜。在随后一个时间点血样采集完成之后,大鼠***麻醉后处死。
血样采集后,立即温和地颠倒试管至少5次,保证混合充分后放置于冰上。血样在4℃5000rpm离心5分钟,将血浆与红细胞分离。用移液器吸出100μL血浆到干净的塑料离心管中,表明化合物的名称和时间点。血浆在进行分析前保存在-80℃。用LC-MS/MS测定血浆中本发明化合物的浓度。药代动力学参数基于每只动物在不同时间点的血药浓度进计算。
实验结果表明,相对于对照化合物flibanserin,本发明化合物在动物体内具有更好的药物动力学,因而具有更好的药效学和治疗效果。
应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围,实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。除非另外说明,否则份数和百分比为重量份和重量百分比。
以上内容是结合具体的优选实施方式对本发明所作的进一步详细说明,不能认定本发明的具体实施只局限于这些说明。对于本发明所属技术领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干简单推演或替换,都应当视为属于本发明的保护范围。
Claims (12)
- 根据权利要求1所述的取代的苯并咪唑酮化合物,其特征在于:R18是三氟甲基
- 根据权利要求1所述的取代的苯并咪唑酮化合物,其特征在于:R1、R2、R3和R4各自独立地为氘或氢。
- 根据权利要求1所述的取代的苯并咪唑酮化合物,其特征在于:R5、R6、R7和R8各自独立地为氘或氢。
- 根据权利要求1所述的取代的苯并咪唑酮化合物,其特征在于:R9、R10、R11、R12、R13、R14、R15和R16各自独立地为氘或氢。
- 根据权利要求1所述的取代的苯并咪唑酮化合物,其特征在于:R17、R19、R20和R21各自独立地为氘或氢。
- 一种药物组合物,其特征在于:其含有药学上可接受的载体和如权利要求1~7任意一项所述的取代的苯并咪唑酮化合物,或其晶型、药学上可接受的盐、水合物或溶剂合物、立体异构体、前药或同位素变体的药物组合物。
- 根据权利要求8所述的药物组合物,其特征在于:其还包含其他治疗药物,所述治疗药物可治疗与5-HT2受体介导的疾病、状况或障碍,其中所述5-HT2受体介导的疾病、状况或障碍选自:体重减轻、肥胖、贪食症、经前期综合症或迟黄体期综合症、抑郁症、非典型性抑郁症、躁狂抑郁性精神病、精神病、精神***症、偏头痛、酒精中毒、烟草滥用、恐慌症、焦虑、创伤后综合征、记忆丧失、老年痴呆、社会恐怖症、注意缺陷障碍伴多动症、破坏性行为障碍、冲动控制障碍、临界人格障碍、强迫性强制障碍、慢性疲乏综合征、雄性性功能障碍、雌性性功能障碍、神经性厌食症、睡眠障碍、孤独症、癫痫发作、癫痫、缄默症、脊髓损伤、中枢神经***损伤、心血管障碍、胃肠道病症、尿崩症,和II型糖尿病。
- 一种如权利要求1~7任意一项所述的取代的苯并咪唑酮化合物,或其晶型、药学上可接受的盐、水合物或溶剂化合物的用途,其特征在于:用于制备治疗、预防以及缓解与5-HT2受体相关的疾病的药物组合物。
- 一种在受试者中治疗和/或预防与5-HT2受体相关疾病的方法,所述方法包括向所述受试者给药如权利要求1~7任意一项所述的式(I)化合物或其多晶型、药学上可接受的盐、前药、立体异构体、同位素变体、水合物或溶剂化合物,或者权利要求8或9任意一项中所述的药物组合物。
- 根据权利要求1~7任意一项所述的式(I)化合物或其多晶型、药学上可接受的盐、前药、立体异构体、同位素变体、水合物或溶剂化合物,或者权利要求8或9任意一项中所述的药物组合物,其用于治疗和/或预防与5-HT2受体相关的疾病。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201680064988.5A CN108349908B (zh) | 2016-02-02 | 2016-12-21 | 一种取代的苯并咪唑酮化合物及包含该化合物的组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610092377.3 | 2016-02-02 | ||
CN201610092377 | 2016-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017133337A1 true WO2017133337A1 (zh) | 2017-08-10 |
Family
ID=59499343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/111193 WO2017133337A1 (zh) | 2016-02-02 | 2016-12-21 | 一种取代的苯并咪唑酮化合物及包含该化合物的组合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108349908B (zh) |
WO (1) | WO2017133337A1 (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003016A1 (en) * | 1991-07-30 | 1993-02-18 | Boehringer Ingelheim Italia S.P.A. | Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2008002693A1 (es) * | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
-
2016
- 2016-12-21 CN CN201680064988.5A patent/CN108349908B/zh active Active
- 2016-12-21 WO PCT/CN2016/111193 patent/WO2017133337A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003016A1 (en) * | 1991-07-30 | 1993-02-18 | Boehringer Ingelheim Italia S.P.A. | Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists |
Also Published As
Publication number | Publication date |
---|---|
CN108349908B (zh) | 2021-07-20 |
CN108349908A (zh) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7252908B2 (ja) | S1p1活性を調節するための化合物およびその使用法 | |
JP5766614B2 (ja) | 神経新生促進化合物 | |
AU2022203486B2 (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
TWI478919B (zh) | 用於治療可受血清素5-ht6受體調節之疾病之喹啉化合物 | |
TWI428334B (zh) | 作為5-ht6拮抗劑之磺醯基吡唑及磺醯基吡唑啉的甲脒衍生物 | |
TW201210582A (en) | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | |
CN102395588A (zh) | 杂环化合物、包含它们的药物组合物及其作为甘氨酸转运蛋白1的抑制剂的用途 | |
TW201211030A (en) | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | |
JP2007535530A (ja) | 中枢神経系障害治療用の置換モルホリン化合物 | |
FR2735127A1 (fr) | Nouvelles piperazines heteroaromatiques utiles comme medicaments. | |
JP5746703B2 (ja) | α7nAChR調節因子としてのインドール及びアザインドール | |
TW201211031A (en) | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | |
CZ20033314A3 (cs) | Použití Q@halogentryptaminových derivátů jako ligandů Q@HT@ a@nebo Q@HT@ receptorů pro serotonin | |
JP6975515B2 (ja) | Trpa1モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物 | |
JP2000503667A (ja) | アルキルアミノベンゾチアゾールおよび―ベンゾキサゾール誘導体 | |
JP5538907B2 (ja) | セロトニン5−ht6受容体の調節に応答する障害を治療する上で好適なキノリン化合物 | |
FR2930249A1 (fr) | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. | |
CN1332740A (zh) | 用于抗抑郁疗法的5-ht1拮抗剂 | |
WO1998031669A1 (fr) | Nouvelles arylpiperazines derivees de piperidine comme medicaments antidepresseurs | |
EP3204374A1 (en) | Isoindoline derivatives | |
WO2017133337A1 (zh) | 一种取代的苯并咪唑酮化合物及包含该化合物的组合物 | |
JP4093588B2 (ja) | 新規インダゾール及びインドロン誘導体及び調合剤としてのそれらの使用 | |
JP2007512285A (ja) | 抗精神病薬としての7−[4−(4−クロロベンジルオキシ)ベンゼンスルホニル]−8−メトキシ−3−メチル−2,3,4,5−テトラヒドロ−1h−3−ベンゾアゼピニウムマレエートもしくはトシレート | |
JP2012525355A (ja) | セロトニン5−ht6受容体の調節に応答する障害を治療するのに適したベンゼンスルホンアニリド化合物 | |
US20110207745A1 (en) | Solid forms of 4--n,n-diethylbenzamide, compositions thereof, and uses therewith |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16889143 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16889143 Country of ref document: EP Kind code of ref document: A1 |